Treatment Experienced Clinical Research Trials

The clinical trials that are available for treatment-experienced AIDS/HIV patients: ACTG A5244, ACTG A5241, and Vicriviroc. All are currently open for enrollment, though the individual requirements and treatments for each study differ.

ACTG A5244

ACTG A5244 is a randomized pilot study to measure treatment intensification with raltegravir on viremia.

Requirements for this study include:

• On ART for greater than 12 months
• HIV RNA <50
• CD4 >200

Treatment will include:

• raltegravir

To become involved, contact Elle Rich:

• Phone: 919-668-1577
• E-mail: elle.rich@duke.edu

ACTG A5241

ACTG A5229 is a randomized strategy study for treatment failure using optimized treatment that includes or omits NRTI.

Requirements for this study include:

• RNA >1000 on PI regimen
• Triple class ARV experience and/or resistance
• Must be naive to integrase inhibitor
• Tropism assay provided by study.

Treatment will include:

• 13 possible treatment regimens based on tropism and phenotype results

To become involved, contact Midge Silberman, RN:

• Phone: 919-668-0177
• E-mail: slibe001@mc.duke.edu

Vicriviroc Study

Safety and efficacy of vicriviroc or placebo in combination with optimized background regime (OBR).

Requirements for this study include:

• Viral load of greater than 1000
• Treatment experienced

Treatment will include:

• Vicriviroc and dual tropism assay provided plus copay covered for OBR.

To become involved, contact Debbie McMullen:

• Phone: 919-668-3759
• E-mail: mcmul006@mc.duke.edu